On Friday, Novavax, Inc (NASDAQ: NVAX) was 1.39% up from the session before settling in for the closing price of $7.22. A 52-week range for NVAX has been $3.53 – $23.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 513.29% over the past five years. When this article was written, the company’s average yearly earnings per share was at 73.90%. With a float of $153.11 million, this company’s outstanding shares have now reached $160.19 million.
Let’s look at the performance matrix of the company that is accounted for 1543 employees. In terms of profitability, gross margin is 66.75%, operating margin of -33.36%, and the pretax margin is -31.6%.
Novavax, Inc (NVAX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 4.42%, while institutional ownership is 58.93%. The most recent insider transaction that took place on Sep 18 ’24, was worth 95,331. Before that another transaction happened on Jun 21 ’24, when Company’s Director sold 7,500 for $14.09, making the entire transaction worth $105,675. This insider now owns 61,760 shares in total.
Novavax, Inc (NVAX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -1.44 earnings per share (EPS) during the time that was less than consensus figure (set at -0.45) by -0.99. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.90% during the next five years compared to 11.55% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.26, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach 0.26 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Novavax, Inc (NASDAQ: NVAX) saw its 5-day average volume 10.25 million, a positive change from its year-to-date volume of 9.8 million. As of the previous 9 days, the stock’s Stochastic %D was 5.33%. Additionally, its Average True Range was 0.77.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 4.64%, which indicates a significant decrease from 13.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.17% in the past 14 days, which was lower than the 98.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.26, while its 200-day Moving Average is $10.03. Nevertheless, the first resistance level for the watch stands at $7.50 in the near term. At $7.67, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.02. If the price goes on to break the first support level at $6.98, it is likely to go to the next support level at $6.63. The third support level lies at $6.46 if the price breaches the second support level.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are 160,185K outstanding shares of the company, which has a market capitalization of 1.19 billion. As of now, sales total 983,710 K while income totals -545,060 K. Its latest quarter income was 415,480 K while its last quarter net income were 162,380 K.
